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Levosimendan Enhances Force Generation of
Diaphragm Muscle from Patients with Chronic
Obstructive Pulmonary Disease
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1Department of Pulmonary Diseases, 2Intensive Care Medicine, and 3Institute for Fundamental and Clinical Human Movement Sciences,
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Rationale: Levosimendan is clinically used to improve myocardial
contractility by enhancing calcium sensitivity of force generation.
The effects of levosimendan on skeletal muscle contractility are
unknown. Patients with chronic obstructive pulmonary disease
(COPD) suffer from diaphragm weakness, which is associated with
decreased calcium sensitivity.
Objectives: To investigate the effects of levosimendan on contrac-
tility of diaphragm fibers from patients with COPD.
Methods: Muscle fibers were isolated from diaphragm biopsies
obtained from thoracotomized patients with and without COPD
(both groups n 5 5, 10 fibers per patient). Diaphragm fibers were
skinned and activated with solutions containing incremental cal-
cium concentrations and 10 mM levosimendan or vehicle (0.02%
dimethyl sulfoxide). Developed force was measured at each step
and force versus calcium concentration relationships were derived.
Results were grouped per myosin heavy chain isoform, which was
determined by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE).
Measurements and Main Results: At sub-maximal activation levo-
simendan improved force generation of COPD and non-COPD di-
aphragm fibers by approximately 25%, both in slow and fast fibers.
Levosimendan increased calcium sensitivity of force generation (P,
0.01) in both slow and fast diaphragm fibers from patients with and
without COPD, without affectingmaximal force generation.
Conclusions: Levosimendan enhances force generating capacity of
diaphragm fibers from patients with and without COPD patients by
increasing calcium sensitivity of force generation. These results pro-
vide a strong rationale for testing the effect of calcium sensitizers on
respiratory muscle dysfunction in patients with COPD.
Keywords: diaphragm; chronic obstructive pulmonary disease; calcium
sensitization; levosimendan
Weakness of the diaphragm frequently occurs in patients with
chronic obstructive pulmonary disease (COPD) (1, 2). Inspira-
tory muscle weakness in these patients is associated with pro-
longed mechanical ventilation and increased mortality (3, 4).
The pathophysiology of inspiratory muscle dysfunction in COPD
is complex (1). Studies have shown that, in patients with COPD,
impaired contractility of muscle fibers from the diaphragm, the
most prominent inspiratory muscle, results from a loss of con-
tractile protein and impaired function of remaining contractile
proteins (5–7). Diaphragm muscle fibers from these patients
exhibit reduced ability to respond to calcium, indicating reduced
calcium sensitivity of force generation. Based on these findings,
we proposed that pharmacological modulation of the regulatory
proteins is an effective strategy to improve diaphragm contrac-
tility in patients with COPD.
Calcium sensitizers enhance the binding of calcium to
regulatory proteins of the contractile apparatus. This improves
the responsiveness of myofilaments to calcium, resulting in
a greater amount of force for the same amount of cytosolic
calcium. An advantage of this mechanism of action is that force
generation is improvedwithout increased adenosine triphosphate
(ATP) consumption (8). Currently, levosimendan is the only
calcium sensitizer approved for use in human (z40 countries
worldwide). Levosimendan has been shown to improve cardiac
contractility in vivo (9) and in vitro (10), by enhancing calcium
sensitivity of force generation through binding with cardiac
troponin C (11). The effects of calcium sensitizers on human
peripheral or respiratory skeletal muscle have not been investi-
gated. Nevertheless, cardiac troponin C isoform is expressed in
human diaphragm muscle. Moreover, Levine and colleagues
have recorded increased expression of this isoform in the di-
aphragm of patients with COPD (12). Therefore, we hypothesize
that levosimendan improves calcium sensitivity of muscle fibers
isolated from the diaphragm of patients with COPD.
METHODS
Subjects
Diaphragm muscle biopsies (z100 mg) were obtained from five
patients with COPD (four males) and five subjects without COPD
(two males). Biopsies from the right anterior costal diaphragm were
obtained during thoracotomy for lung cancer (stage T1–3N0–1Mx).
Stages of lung cancer did not significantly differ between patients with
COPD and those without COPD. Patients with chronic corticosteroid
use, primary myopathies, endocrine diseases, and more than 10%
weight loss in the last 6 months before surgery were excluded from the
study. General characteristics and pulmonary function data are shown
in Table 1. Informed consent was obtained from each subject. The
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Loss of contractile protein and impaired calcium sensitivity
of force generation contribute to respiratory muscle dys-
function in patients with chronic obstructive pulmonary
disease (COPD). No specific treatment exists to improve
respiratory muscle function in these patients.
What This Study Adds to the Field
The calcium sensitizer levosimendan improves contractile
protein function in diaphragm muscle fibers of patients
with COPD.
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study was approved by the Ethics Committee of Radboud University
Nijmegen Medical Centre.
Single Fiber Contractile Measurements
According to previously described methods (5, 13), single fiber con-
tractile measurements and experimental protocol were performed as
follows.
Single Fiber Preparation
A bundle was dissected from the central part of the fresh muscle
biopsy. The muscle bundle was pinned to cork and stored at 48C in
a relaxing solution, containing 50% glycerol (vol/vol). After 24 hours,
the muscle strip was stored at 2208C for later analysis. Approximately
1 hour before determination of single fiber contractile properties, the
muscle bundle was transferred to relaxing solution (58C) containing 1%
Triton X-100 to permeabilize lipid membranes. From the muscle
bundle, approximately 2-mm segments of single fibers were isolated
using micro-forceps. Subsequently, the fiber ends were attached to
aluminum foil clips and mounted on the single fiber apparatus. Fibers
were mounted in a temperature-controlled (208C) flow-through acrylic
chamber (120-ml volume), with a glass coverslip bottom, on the stage
of an inverted microscope (model IX-70; Olympus, Amsterdam, The
Netherlands).Two stainless steel hooks were used to mount the fiber
horizontally in the chamber. One end of the fiber was attached to
a force transducer (model AE-801; SensoNor, Horten, Norway) with
a resonance frequency of 10 kHz, whereas the other end was attached
to a servomotor (model 308B; Aurora Scientific, Aurora, ON, Canada)
with a step time of 250 ms. In relaxing solution, sarcomere length was
set at 2.4 mm as the optimal length for force generation (14, 15) with
the use of a calibrated eyepiece micrometer. Muscle fiber length (z1–
1.5 mm) was measured using a reticule in the microscope eyepiece
(310 Olympus Plan 10,0.30 numerical aperture [NA]). The XY fiber
diameter (width) was measured with a 340 objective (340 Olympus
Plan 40, 0.60 NA). The 340 objective also was used to measure the XZ
fiber diameter (depth) by noting the displacement of the microscope’s
objective while focusing on the top and bottom surfaces of the fiber.
Three width and depth measurements were made along the length of
the fiber, and the average values were used to calculate the fiber cross-
sectional area, assuming that the fiber was ellipsoid in shape.
Composition of Solutions for Single Fiber Measurements
Concentrated stock solutions of levosimendan (a kind gift from Orion
Pharma, Espoo, Finland) were prepared in dimethyl solfoxide (DMSO)
and stored at 2208C. Before use, levosimendan stock solutions were
diluted with experimental solutions. The final concentration of DMSO
did not exceed 0.02%. Control experimental solutions contained 0.02%
DMSO (vehicle). Relaxing solution consisted of 1.0 mMMgCl2, 4.0 mM
Na2ATP, 5mMethyleneglycol-bis-(b-aminoethyl ether)-N,N9-tetraacetic
acid (EGTA), 10 mM imidazole, 15 mM creatine phosphate, and
sufficient KCL to adjust the total ionic strength to 150 mM at pH 7.0.
The negative logarithm of the free Ca21 concentration (pCa) of the
relaxing solution was 9.0, whereas in activating solutions the pCa ranged
from 7.0 to 4.5 (withmaximal activation at pCa 4.5). Sufficient CaCl2 was
added to achieve appropriate pCa in activating solutions.
Diaphragm Muscle Single Fiber Experimental Protocol
The response of five COPD diaphragm fibers to different doses of
levosimendan was determined during submaximal activation (at pCa
5.8). Figure 1 shows that levosimendan enhanced submaximal force
generation with a maximal effect at 10 mM, which is in accordance with
previously reported dose–response curves for cardiac fibers (10). Accord-
ingly, further experiments were conducted with either levosimendan
(10 mM) or vehicle. Maximal force was determined by perfusing the
experimental chamber with solutions of, successively, pCa 9 and pCa 4.5.
Then pCa 9.0 solution was perfused through the chamber to relax the
fiber. Subsequently, fibers were perfused with solutions containing
incremental Ca21 concentrations. Each time a plateau was reached,
the next pCa solution was perfused through the experimental chamber.
To improve functional stability of muscle fibers, we applied Brenner
cycling (16), asmodified by Sweeney and colleagues (17), throughout the
experimental protocol. Accordingly, no functional decline in maximal
force generation over time was observed. MIDAC software (Radboud
University, Nijmegen, The Netherlands) and a data-acquisition board
were used to record signals.
Diaphragm Muscle Single Fiber Contractile Determinations
Maximum specific force was determined by dividing the isometric force
generated at pCa 4.5 by cross-sectional area (CSA). The force–pCa
relationship was derived by plotting recorded force against pCa of the
corresponding activating solution. Graphpad software (Graphpad
Software Inc., San Diego, CA) was used to calculate the Ca21
concentration required for half-maximum activation, pCa50 (pCa 5
210log[Ca21]), as an index of Ca21 sensitivity of force generation and
the Hill coefficient, as a measure of myofilament cooperativity (18).
Myosin Heavy Chain Isoform Composition Determination
Because pCa50 is significantly different between slow and fast di-
aphragm fibers (19), diaphragm fibers were designated as slow or fast
on the basis of myosin heavy chain isoform determination. Determi-
nation of myosin heavy chain isoform composition by SDS-PAGE was
described previously (13).
TABLE 1. PATIENT CHARACTERISTICS
Patients
Age
(yr)
BMI
(kg/m2)
FEV1 (%
predicted)
VC (%
predicted)
FEV1/VC
(%)
TLC (%
predicted)
DLCO/VA (%
predicted)
Non-COPD
Female 59 23 83 102 74 88 87
Male 61 27 106 110 73 118 98
Female 50 21 98 120 72 115 45
Female 63 23 126 139 74 108 87
Male 66 21 83 79 78 77 113
COPD
Male 73 24 86 125 68 112 102
Male 62 24 60 114 52 111 73
Female 61 21 54 105 42 124 64
Male 60 27 85 104 61 106 91
Male 44 23 29 90 26 133 51
Definition of abbreviations: BMI 5 body mass index; DLCO/VA 5 carbon
monoxide transfer coefficient per alveolar volume.
Figure 1. Dose–response effects of levosimendan on diaphragm fiber
submaximal force-generating capacity. Incremental levosimendan con-
centrations were added to diaphragm fibers (n 5 5) from patients with
chronic obstructive pulmonary disease during sub-maximal activation
at pCa 5.8. Force generation increases with rising levosimendan
concentration, with a maximal effect at 10 mM.
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Data Treatment and Statistical Methods
Differences regarding force–pCa relations between groups were statis-
tically analyzed with a two-way repeated measures analysis of variance
(ANOVA) test with pCa as the repeated measures factor and the
presence of levosimendan as the second factor. One-way ANOVA with
post hoc Student-Newman-Keuls testing was performed to evaluate the
statistical significance of differences between groups of other contractile
characteristics. A probability level of P , 0.05 was considered signifi-
cant. Mean 6 SEM values are presented in text, tables, and figures.
Sample size of 25 fibers (i.e., 12–13 per treatment group), calculated
a priori, was based upon the assumption to detect an increase of
submaximal force of at least 15% by 10 mM levosimendan (10) with
a standard deviation of 15% (5), 80% probability, and an a level of
0.05. Because we determined the effect in both slow and fast fibers,
a total of 100 diaphragm fibers obtained from five patients with COPD
and five non-COPD patients were measured (i.e., 10 fibers per patient;
five with 10 mM levosimendan and five with vehicle).
RESULTS
Patient Characteristics
Patient characteristics and pulmonary function data are shown in
Table 1. Based on Global Initiative for Chronic Obstructive
Lung Disease (GOLD) classification, two patients had mild
COPD (stage I), two patients had moderate COPD (stage II)
and one patient was classified as very severe COPD (stage IV).
One patient without COPD had a mild restriction, and another
patient without COPD had a reduced lung diffusion capacity.
Diaphragm Fiber Contractility
Levosimendan increased calcium sensitivity of force generation
in diaphragm fibers from patients with and without COPD,
which is indicated by a leftward shift of the force–pCa relation
in levosimendan-exposed fibers (Figure 2). During submaximal
activation, for instance at pCa 6.0, levosimendan increased
diaphragm fiber force by 20 to 30% compared with vehicle-
exposed fibers. Accordingly, the pCa50, a measure for calcium
sensitivity of force generation, is higher in levosimendan-treated
fibers than in vehicle-treated fibers for both COPD and non-
COPD diaphragm fibers (Figure 3). Separation of the results
into fibers expressing slow or fast myosin heavy chain showed
that levosimendan’s effect was more pronounced in slow fibers
(Figure 3A) than in fast fibers (Figure 3B). Myofilament
cooperativity, indicated by the Hill coefficient, did not differ
between vehicle and levosimendan-treated fibers; for slow non-
COPD fibers (1.476 0.11 vs. 1.776 0.22), for slow COPD fibers
(1.55 6 0.16 vs. 1.30 6 0.13), for fast non-COPD fibers (2.85 6
0.18 vs. 3.09 6 0.73) and for fast COPD fibers (3.18 6 0.56 vs.
2.02 6 0.18). Also, levosimendan did not significantly affect
diaphragm fiber maximal force generation in both COPD and
non-COPD fibers (Figure 4).
COPD Versus Non-COPD
The effect size of levosimendan on calcium sensitivity did not
differ between COPD and non-COPD diaphragm fibers, for
both slow and fast typed fibers (Figure 3). Vehicle-treated
COPD fibers displayed lower calcium sensitivity and maximal
force-generating capacity compared with vehicle-treated fibers
from patients without COPD (Figures 3 and 4), which confirms
our previously published data (5).
DISCUSSION
The present study is the first to show that pharmacological
modulation of the troponin complex improves human dia-
phragm muscle fiber contractility. Recently, we have shown
that calcium sensitivity of force generation in the diaphragm of
patients with COPD is impaired (5). Data of the present study
confirm these findings and show that levosimendan improves
calcium sensitivity in diaphragm muscle fibers of these patients.
Interestingly, levosimendan also improved calcium sensitivity of
diaphragm fibers from the diaphragm of patients without
COPD. Under certain conditions, calcium sensitization offers
a promising mechanism for the treatment of diaphragm weak-
ness, especially in patients with COPD.
Respiratory failure is a prominent manifestation in COPD
and is characterized by an increased energy demandonweakened
respiratory muscles (1). Increasing the workload on weakened
respiratory muscle leads to reduced efficiency of respiratory
muscles, which further restricts the limited energy reserves of
the diseased body (20, 21). To break this viscous circle it is
therefore clinically relevant to seek therapies that improve the
efficiency of respiratory muscles. Levosimendan has been de-
veloped in attempts to find solutions for similar questions re-
garding cardiac muscle (22). The positive inotropic effects of
levosimendan are thought to result mainly from calcium sensiti-
zation of cardiac muscle fibers (23). In vivo, both the heart
and diaphragm muscle undergo repetitive cycles of contraction
and relaxation. This requires continuous sequestration of calcium
at the muscle fiber level, which is an energy-consuming process
that comprises 30 to 40% of total muscle energy consumption
during normal contractions (24). Current and previous (5) data
show that more calcium is needed in diaphragm fibers from
patients with COPD to generate the same amount of force as
patients without COPD. Accordingly, the stimulation frequency
of diaphragm fibers should be increased. Indeed, discharge
frequency of motor neurons that activate the diaphragm is
twofold higher in patients with COPD during resting breathing
(25). This will however impose a higher burden on the calcium
sequestration, rendering diaphragm performance less efficient.
Conversely, improvement of diaphragm efficiency could be
established by generating the same amount of force with less
calcium (i.e., increasing the sensitivity of myofilaments for
calcium). The present study demonstrates that levosimendan
does increase the calcium sensitivity of diaphragm fibers from
patients with COPD.
Mechanisms of Action
In cardiac muscle, levosimendan is presumed to increase calcium
sensitivity by stabilizing the conformation of the troponin com-
plex, which triggers muscle contraction (26). Indeed, troponin C
has been shown to interact with levosimendan in cardiac muscle
(11). Two isoforms of troponin C exist in muscle tissue: the
cardiac/slow isoform present in cardiac and slow-type skeletal
muscle, and the fast isoform present in fast-type skeletal muscles.
The present finding, that levosimendan improves contractility of
slow diaphragm fibers, can be explained by its interaction with
cardiac/slow troponin C. In addition, we observed that levosi-
mendan enhances fast diaphragm fiber contractility. Fast skeletal
and slow skeletal troponin C are approximately 70% identical
(27), but whether levosimendan can also bind to fast troponin C
has, as far as we know, never been described. Our observations in
fast diaphragm fibers suggest a possible interaction of levosimen-
dan with fast troponin C. Another possibility is that some fibers
express fast myosin heavy chain with slow troponin C. Increased
expression of slow troponin C has previously been demonstrated
in the diaphragm of patients with COPD (12). It was postulated
that this results from a reduction of fast fibers rather than an
altered isoform expression within fast fibers. Our results support
this postulation, because the effect size of levosimendan on
COPD fibers was similar to its effect size on non-COPD fibers.
Furthermore, adult skeletal muscle generally coexpresses fast
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myosin heavy chain with fast troponin C (28), so we do not expect
that expression of slow troponin C explains the effect of levosi-
mendan in fast fibers.Nevertheless, the effect of levosimendan on
pCa50 was more profound in slow fibers compared with fast fibers
(Figure 2), indicating that the effect size of levosimendandepends
on the isoform expression ofmyofibrillar proteins.A recent study
showed that specific structures in troponin I influence the binding
of levosimendan to the troponin complex. It could therefore be
that the effect size of levosimendan is modulated by isoforms of
different myofibrillar proteins. As expression of type I fibers in
the diaphragm of patients with COPD is increased (12) levosi-
mendan treatment may be more effective in patients with COPD
than in healthy subjects. Levosimendan did not affect maximal
force generation, which implies that the maximal amount of
attached cross-bridges as well as force per cross-bridge was not
affected by levosimendan.
Study Limitations
The effect of levosimendan on diaphragm muscle fibers was
tested in vitro, which brings several advantages. Using skinned
muscle fibers we were able to specifically study the effects of
levosimendan on contractile protein function. This would not be
possible in vivo because measured force in vivo depends on
many other factors including patient motivation, neuromuscular
transmission, and intracellular calcium signaling. In addition,
the cardiovascular effects of levosimendan may affect respira-
tory muscle function in patients with COPD. Thus, skinned
diaphragm fibers provide an excellent model to study the effects
of levosimendan on diaphragm contractility. The data of the
present study provide a strong rationale to test the effects of
calcium sensitizers on diaphragm muscle function in vivo under
appropriate conditions.
The levosimendan concentration used in the present study
(10 mM) was derived from dose–response study and was in line
with previous data from cardiac muscle fibers (10). Although
0.1 mM levosimendan resulted in enhanced force generation,
the dose–response curve on COPD diaphragm fibers revealed
that 10 mM levosimendan induces a maximal effect on force
improvement. This concentration is slightly higher than plasma
concentrations measured after infusion using clinically recom-
Figure 2. Force-calcium characteristics
of diaphragm fibers from patients with
and without chronic obstructive pulmo-
nary disease in the presence of 10 mM
levosimendan or vehicle activating solu-
tions. Isometric force generation in re-
sponse to solutions with incremental
calcium concentrations was determined.
Submaximal force generation is higher in
diaphragm fibers treated with levosimen-
dan when compared with vehicle. *Two-
way repeated measures analysis showed
that force-pCa relations of fibers treated
with levosimendan were significantly dif-
ferent from force-pCa relations of fibers
treated with vehicle, for both slow and
fast fibers (A and B, respectively). Data
are presented as means 6 SEM.
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mended dosages (24-h infusion with 0.1–0.4 mg/kg/min) (29).
Furthermore, intracellular levosimendan concentrations seem
to be more relevant and could exceed blood values. Local
concentrations are, however, difficult to determine because
in vivo levosimendan has a short half-life (z1 h) as it is reduced
to OR-1855 by intestinal bacteria (30). OR-1855 is further meta-
bolized by acetylation to OR-1896, which has similar calcium
sensitizing properties as levosimendan (23), but a much longer
half-life (30).
Clinical Implications
The pathophysiology of weaning failure from mechanical venti-
lation is complex and multifactorial (31). However, it has been
recognized that, in patients with COPD, maximal inspiratory
pressure is significantly lower at the time of weaning failure than
at the time of successful weaning (32). In addition, patients with
severe COPD failing to wean from mechanical ventilation
generate lower inspiratory transdiaphragmatic pressure than
patients without severe COPD (33). Accordingly, improving
respiratory muscle contractility may contribute to successful
weaning from mechanical ventilation in these patients. More-
over, as levosimendan also improves contractility in diaphragm
fibers from patients without COPD, this agent may appear
beneficial to other patients difficult to wean from mechanical
ventilation. The results of the present study provide an excellent
rationale to test the efficacy of levosimendan in this clinical
setting. However, it should be kept in mind that in vivo levosi-
mendan affects other cell processes besides calcium sensitivity.
For instance, opening of ATP-sensitive potassium channels in
vascular smooth muscle affects pulmonary and systemic vascular
Figure 4. Maximal force generation of diaphragm fibers from patients
with and without chronic obstructive pulmonary disease (COPD) in the
presence of 10 mM levosimendan or vehicle solution. COPD diaphragm
fibers generated lower maximal forces than non-COPD fibers, in both
slow and fast fibers (Figures 4A and 4B, respectively). Maximal force
generation is not significantly different between levosimendan and
vehicle-treated fibers within patient groups. Data are presented as
means 6 SEM. *P , 0.05 compared with vehicle-treated non-COPD
fibers within fiber-type group.
Figure 3. Values of pCa50, an index for calcium sensitivity of force
generation, from diaphragm fibers of patients with and without chronic
obstructive pulmonary disease (COPD) in the presence of 10 mM
levosimendan or vehicle solution. Calcium sensitivity is lower in COPD
fibers than in non-COPD fibers. Diaphragm fibers treated with levosi-
mendan display higher calcium sensitivity than fibers treated with
vehicle, for both slow and fast fibers (A and B, respectively). Data are
presented as means 6 SEM. *P , 0.01 compared with vehicle-treated
fibers within subject group; #P , 0.05 compared with vehicle treated
non-COPD fibers within fiber-type group. pCa50 5 210log[Ca21] at
which 50% of maximal force is generated.
van Hees, Dekhuijzen, and Heunks: Levosimendan in COPD Diaphragm 45
resistance, resulting in reduction in mean arterial blood pressure
(34). The final effects of levosimendan on cardiac contractility,
respiratory muscle function, and oxygen transport in non–heart-
failure patients are difficult to predict but should be answered by
clinical studies. By increasing pCa50 levosimendan could improve
respiratory muscle function during weaning without increasing
energy expenditure. The latter is important because respiratory
muscles could fatigue during weaning trails (32, 35). A major
cause of fatigue is the accumulation of inorganic phosphate
resulting from the excessive breakdown of phosphocreatine
during periods of high energy demand (36). Elevated inorganic
phosphate levels depress calcium sensitivity (37), which evidently
impairs contractile muscle function. Hence, levosimendan seems
highly appropriate to counteract fatigue-induced muscle weak-
ness because it enhances the sensitivity for calcium without
increasing energy demand. Very recently, Levine and colleagues
showed that controlled mechanical ventilation induces rapid
atrophy of human diaphragm muscle fibers (38). Although not
studied, it is likely that atrophy will result in impaired diaphragm
contractility in these patients. Therefore, levosimendan may
appear beneficial in difficult mechanical ventilation weaning of
patients without COPD as well. Our study demonstrated that
levosimendan increased calcium sensitivity of diaphragm fibers
from subjects without COPD.
Levosimendan is generally well tolerated by patients and
hypotension is one of the most observed side effects but is not
common when the treatment remains within the recommended
dose. If necessary, hypotension can be counteracted by low-dose
norepinephrine (39, 40).
In conclusion, the present study demonstrates that levosi-
mendan enhances the force-generating capacity of diaphragm
fibers from patients with and without COPD by increasing
calcium sensitivity of force generation. The results of our study
provide a strong rationale for testing the effect of calcium
sensitizers on respiratory muscle contractility in patients with
COPD during elevated loading, such as weaning from mechan-
ical ventilation.
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